Skip to main content
Careers
Contact us
Company
About Us
Management
Board of Directors
Advisory Board
Therapeutic Focus
Neurological Disorders
Chronic Pain
Hair Loss Disorders
Science and Technology
Exicure's Approach
References and Papers
Pipeline
Pipeline
Collaboration Programs
Partnering and Licensing
Investors
Investors
News
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Form 8937
Financials
Interactive Financials
Financial Summary
SEC Filings
Annual Reports
Governance
Executive Management
Board of Directors
Governance Documents
Committee Composition
Resources
Contact IR
FAQs
Email Alerts
News
Company
About Us
Management
Board of Directors
Advisory Board
Scientific Team
Therapeutic Focus
Genetic Disorders
Oncology
Science and Technology
Pipeline
Pipeline
AST-008
XCUR-FXN
Collaboration Programs
Compassionate Use Policy
Partnering and Licensing
Investors
Investors
News
Events & Presentations
Stock Info
Stock Quote & Chart
Analyst Coverage
Form 8937
Financials
Interactive Financials
Financial Summary
SEC Filings
Annual Reports
Governance
Executive Management
Board of Directors
Governance Documents
Committee Composition
Resources
Contact IR
FAQs
Email Alerts
Normal
Press release year list
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
12/29/2020
Exicure Announces Webcast of Presentation at 2021 HC Wainwright BIOCONNECT Conference
12/28/2020
Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day
12/21/2020
Exicure Announces Issuance of Two New U.S. Patents and A New Patent Allowance Covering Cavrotolimod Through 2034
11/16/2020
Exicure to Participate in Upcoming Conferences
11/12/2020
Exicure, Inc. Reports Third Quarter 2020 Financial Results and Corporate Progress
11/09/2020
Exicure Presents Positive Clinical Data with Cavrotolimod at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
10/19/2020
Exicure Announces Phase 1b Poster Presentation at The Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
10/05/2020
Exicure to Present at the Chardan Virtual 4th Annual Genetic Medicines Conference
10/01/2020
Exicure Secures Debt Facility for Up to $25.0 Million
09/16/2020
Exicure Presents Promising Interim Results from Ongoing Phase 1b/2 Trial of Cavrotolimod at Virtual KOL Event Today
09/10/2020
Exicure to Present at Upcoming Conferences
08/25/2020
Exicure Announces a Virtual KOL Meeting to Discuss Preliminary Phase 1b Efficacy Data for Cavrotolimod
08/12/2020
Exicure, Inc. Reports Second Quarter 2020 Financial Results and Corporate Progress
08/05/2020
Exicure, Inc. to Present at the BTIG Virtual Biotechnology Conference 2020
06/29/2020
Exicure, Inc. Added to Russell 2000® Index
06/22/2020
Exicure Presents Cavrotolimod (AST-008) Clinical Data at AACR 2020 Virtual Meeting
06/18/2020
Exicure, Inc. to Present at the 2020 BMO Prescription for Success Healthcare Conference
06/16/2020
Exicure Announces First Patient Dosed in Phase 2 Merkel Cell Carcinoma Trial of Cavrotolimod (AST-008)
05/20/2020
Exicure, Inc. to Present at Jefferies 2020 Healthcare Conference
05/19/2020
Exicure Announces Appointment of Dr. Douglas E. Feltner as Chief Medical Officer
05/15/2020
Exicure to Present Clinical Data at AACR 2020 Virtual Meeting
05/14/2020
Exicure to Present at the American Society of Clinical Oncology 2020
05/14/2020
Exicure, Inc. Reports First Quarter 2020 Financial Results and Corporate Progress
05/05/2020
Exicure to Present AST-008 Updates at 2020 AACR Virtual Annual Meeting
04/07/2020
Exicure, Inc. Announces Appointment of Timothy P. Walbert as Chairman of the Board
Download
PDF format download (opens in new window)
03/30/2020
Exicure Provides Business Update Amid COVID-19 Pandemic
Download
PDF format download (opens in new window)
03/03/2020
Exicure, Inc. Reports Full Year 2019 Financial Results and Corporate Progress
Download
PDF format download (opens in new window)
03/02/2020
Exicure to Present at the Cowen 40th Annual Healthcare Conference
Download
PDF format download (opens in new window)